ClinicalTrials.gg
RecruitingNCT07468344SAUNA-HF RCTUpdated Oct 29, 2026

Evaluation of the Effects of Sauna Therapy on Congestion and Loop Diuretic Use in Patients With Heart Failure With Reduced or Moderately Reduced Ejection Fraction

An interventional study of Sauna in Heart Failure, sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Central Hospital, Nancy, France · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 29, 2026Now RecruitingEligibility revised+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Heart Failure by Central Hospital, Nancy, France — 9 open to participants now, 10 under way, 1 of them phase 3. Heart Failure · Central Hospital, Nancy, France.

Planned enrollment
12th of 13
46 · median 103
Started
2026
the only one that year
No phase
12 of 19
8 open now
Registered
19th of 19
by date

Among the 19 studies in Heart Failure by Central Hospital, Nancy, France, this one is the 12th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2026, is one of 12 with no phase, and was the 19th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

9 of the 19 studies in Heart Failure by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Heart Failure by Central Hospital, Nancy, France, or all of them as a file.
02

Study summary

This study aims to evaluate the effect of sauna therapy on congestion levels during cardiac rehabilitation in patients with heart failure who have an impaired or moderately impaired ejection fraction, compared to standard cardiac rehabilitation care. To investigate this, patients with reduced cardiac function who are hospitalized as part of a cardiac rehabilitation program will be included. These patients will be randomly assigned to two groups: standard cardiac rehabilitation program (control group) and sauna group (intervention group). The study will also assess whether this approach could allow for a reduction in the dose of diuretics, which are commonly used to remove excess fluid, thereby helping to avoid certain side effects. The expected benefits include a reduction in symptoms such as shortness of breath and swelling, improvements in quality of life and physical fitness, and enhanced blood vessel function.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • congestion
  • sauna
  • heart failure
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Heart failure with \<50% confirmed by an echocardiogram within the past year.
  • class II-III.
  • Loop diuretic dose ≥ 40 mg/day of furosemide (or equivalent) for at least 30 days.
  • NT-proBNP > 400 pg/ml or BNP > 100 pg/ml.
  • Estimated (eGFR) ≥ 20 ml/min/1.73 m².
  • Patient scheduled for a hospital-based cardiac rehabilitation program for a minimum of 3 weeks.
  • Person who has undergone a preliminary clinical examination suitable for clinical research.
  • Person affiliated with a social security system or a beneficiary of such a system.
  • Person who has received complete information about the organization of the clinical research and has signed .

Exclusion criteria

Exclusion Criteria:

  • Person presenting a to sauna therapy (for example, intolerance to heat).
  • Serum sodium \< 130 mmol/L.
  • Serum potassium > 5.5 mmol/L.
  • Active infection, liver disease, or peripheral vascular disease.
  • Acute coronary syndrome or recent stroke (\<90 days).
  • Participation in another interventional clinical trial.
  • Person subject to Articles L. 1121-5, L. 1121-7, and L. 1121-8 of the Public Health Code (applicable in France) :- pregnant, giving birth, or breastfeeding woman , minor (non-emancipated), person adult subject to a legal protection measure (guardianship, curatorship, judicial protection) , adult unable to express consent, persons deprived of liberty by judicial or administrative decision, persons receiving psychiatric care under Articles L. 3212-1 and L. 3213-1…
  • Person who objects to the processing of their data for quality control purposes
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Sauna

    A 15-minute sauna session at 60 degrees Celsius during hospitalization for cardiac rehabilitation.

    Device: Sauna

  • No intervention
    Control

    Usual care as part of a day hospital stay for cardiac rehabilitation.

Interventions

  • DeviceSauna

    A 15-minute sauna session at 60 degrees Celsius, five times a week for three weeks during hospitalization for cardiac rehabilitation. The sauna sessions will be followed by 30 minutes of recovery in a seated position. In addition to the sauna, patients will benefit from cardiac rehabilitation care for 3 weeks.

06

What researchers measure

Primary outcomes

  1. Median change in NT-proBNP levels.

    Time frame: Between randomization and the end of the third week.

Secondary outcomes

  1. Daily dose of loop diuretics.

    Time frame: Day 1, end of weeks 1, 2, and 3, and 3-month follow-up.

  2. Weight in kilograms.

    Time frame: Day 1, end of weeks 1,2 and 3, and 3-month follow-up.

  3. Congestion score: ADVoR congestion score.

    ADVoR congestion score is a grading scale taking account oedema, pleural effusion and ascites. The score can range from 0 to 10 with "0" being the best result meaning " no congestion " and "10" the worst meaning " maximum congestion ".

    Time frame: Day 1, end of week 3, and 3-month follow-up.

  4. Congestion score: Ambrosy congestion score.

    Ambrosy congestion score is a grading scale taking account dyspnoea, orthopnoea, jugular venous distension, rales and oedema. The score can range from 0 to 18, "0" being the best outcome (no congestion) and "18" the worst outcome (maximum congestion).

    Time frame: Day 1, end of week 3, and 3-month follow-up.

  5. Estimated plasma volume (EPV): Duarte formula.

    Time frame: Day 1, end of week 3, and 3-month follow-up.

  6. Dyspnea visual analog scale: Cumulative dyspnea assessment (AUC).

    The minimum value is "0" (best outcome) and means "no dyspnea". The maximum value is "10" (worst outcome) and means "maximum dyspnea".

    Time frame: Day 1, beginning of weeks 2 and 3.

  7. Concentration of natriuretic peptides (NT-proBNP).

    Time frame: Day 1, end of week 1, beginning and end of week 2, beginning and end of week 3, and 3-month follow-up.

  8. Evaluation of renal function through rate of serum creatinine allowing to estimate glomerular filtration rate.

    Estimate glomerular filtration rate is calculated by the following formula : Clearance (mL/min) = weight (kg) x (140-age) x K / serum creatinine (μmol/L) ; K=1.23 for man and 1.04 for woman.

    Time frame: End of weeks 1, 2, and 3 and 3-month follow-up.

  9. Evaluation of renal function through renal function assessment.

    Time frame: Day 1 and end of week 3.

  10. Dose of diuretics.

    Time frame: Day 1, end of weeks 1, 2, and 3, and 3-month follow-up.

  11. Concentration of serum electrolytes (Cl-, Na+, K+).

    Time frame: Day 1, end of weeks 1, 2, and 3, and 3-month follow-up.

  12. Blood osmolality in mmol/L.

    Blood osmolality in mmol/L is calculated using natremia, glycemia and uremia. The formula is : Natremia in mmmol/L\*2 + glycemia in mmol/L \*5.56 + uremia in mmol/L\*16.6.

    Time frame: Day 1, end of weeks 1, 2, and 3, and 3-month follow-up.

  13. Concentration of urinary electrolytes (Cl-, Na+, K+).

    Time frame: Day 1, end of weeks 1, 2, and 3, and 3-month follow-up.

  14. Urinary osmolality in mmol/L.

    Urinary osmolality in mmol/L is calculated using natremia, glycemia and uremia. The formula is : (natremia in mmol/L + kaliemia in mmol/L+ chloride in mmol/L) + (glycemia in mmol/L\*5.56) + (uremia in mmol/L\*16.6).

    Time frame: Day 1, beginning and end of weeks 1, 2, and 3, and 3-month follow-up.

  15. Hemoconcentration biomarkers : Hct.

    Hemoconcentration was assessed using hematocrit (%).

    Time frame: Day 1, end of weeks 1, 2, and 3, and 3-month follow-up.

  16. Hemoconcentration biomarkers : Hb.

    Hemoconcentration was assessed using hemoglobin (g/dL).

    Time frame: Day 1, end of weeks 1, 2, and 3, and 3-month follow-up.

  17. Hemoconcentration biomarkers : total protein.

    Hemoconcentration was assessed using total protein (g/L).

    Time frame: Time Frame: Day 1, end of weeks 1, 2, and 3, and 3-month follow-up.

  18. Hemoconcentration biomarkers : copeptin.

    Hemoconcentration was assessed using copeptin concentrations (pmol/L).

    Time frame: Time Frame: Day 1, end of weeks 1, 2, and 3, and 3-month follow-up.

  19. Inferior vena cava diameter (millimeters, mm) measured by transthoracic echocardiography during inspiration.

    The inferior vena cava (IVC) diameter will be measured in millimeters using transthoracic echocardiography.

    Time frame: Day 1, end of week 1, beginning and end of week 2, beginning and end of week 3, and 3-month follow-up.

  20. Inferior vena cava diameter (millimeters, mm) in expiration measured by transthoracic echocardiography during expiration.

    IVC diameter will be measured in millimeters using transthoracic echocardiography.

    Time frame: Day 1, end of week 1, beginning and end of week 2, beginning and end of week 3, and 3-month follow-up.

  21. Inferior vena cava respiratory variation / collapsibility index (percentage, %) assessed by transthoracic echocardiography.

    VCI respiratory variation will be assessed using transthoracic echocardiography and expressed as the collapsibility index. Collapsibility index will be measured as the ratio between IVC diameter in inspiration (outcome 17) and IVC diameter in expiration (outcome 18) expressed in %.

    Time frame: Day 1, end of week 1, beginning and end of week 2, beginning and end of week 3, and 3-month follow-up.

  22. Lung ultrasound score (8 points).

    Evaluation of lung comet presence measured by an 8-points lung echography and rated on a scale ranging from 0 (minimum - best outcome : no congestion) to 10 (maximum - worst outcome : maximum congestion) per point.

    Time frame: Day 1, end of week 3, and 3-month follow-up.

  23. Quantification of changes in systolic and diastolic function.

    Time frame: Day 1 and 3-month follow-up.

  24. Heart rate in Beats Per Minute (BPM).

    Time frame: Multiple daily measurements : 4 times a day, 5 days a week for 3 weeks.

  25. Heart rate variability in millisecond (ms).

    Time frame: Multiple daily measurements : 4 times a day, 5 days a week for 3 weeks.

  26. Blood pressure in mmHg.

    Blood pressure will be measured daily for 3 weeks and at 3-month follow-up.

    Time frame: Up to 3 weeks and at 3-month follow-up.

  27. Monitoring of changes in pulmonary blood pressure.

    Changes in pulmonary blood pressure will be measured with echocardiography.

    Time frame: Day 1 and at 3-month follow-up.

  28. Composite clinical endpoint of hospitalization or emergency visits for heart failure or all-cause death.

    Time frame: At 3-month follow-up.

  29. Body composition parameters assessed by bioelectrical impedance analysis.

    Evaluation of the patient's body composition parameters. This measure includes the assessment of fluid distribution-Total Body Water (TBW), Intracellular Water (ICW), and Extracellular Water (ECW)-as well as tissue compartments: body protein mass, body mineral mass, and fat mass. The device records multiple parameters, the analysis will focus specifically on these pre-specified indicators of body composition.

    Time frame: Day 1, end of Week 1, beginning and end of Week 2, beginning and end of Week 3, and at 3-month follow-up.

  30. Specific to the sauna group : weight in kilograms.

    Weight will be measured before and after each sauna session.

    Time frame: Up to 3 weeks.

  31. Specific to the sauna group : blood pressure in mmHg.

    Blood pressure will be measured before and after each sauna session.

    Time frame: Up to 3 weeks.

  32. Specific to the sauna group : temperature in °C.

    Temperature will be measured before and after each sauna session.

    Time frame: Up to 3 weeks.

  33. Specific to the sauna group : heart rate in Beats Per Minute (BPM).

    Heart rate will be measured continuously during each sauna session.

    Time frame: Up to 3 weeks.

  34. Specific to the sauna group : sodium chloride concentration in sweat.

    The concentration of sodium chloride in sweat will be measured during one sauna session per week (three measurements in total).

    Time frame: Up to 3 weeks.

  35. Handgrip stenght test

    Handgrip stenght will be measured using a dynamometer.

    Time frame: Day 1 and at the end of Week 3.

07

Study locations

1 of 1 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Sep 2027, 15 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 15 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Apr 2026 → Jun 2026, primary completion Jul 2027 → Sep 2027 and completion Jul 2027 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Mar 12, 2026
StartActual
Jun 23, 2026was Apr 2026
Primary completionEst.
Sep 23, 2027was Jul 2027
CompletionEst.
Sep 23, 2027was Jul 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 22, 2026
Sites
Centre Hospitalier Régional Universitaire de Nancy is now Recruiting
Oct 22, 2026
Start date
Apr 2026→Jun 23, 2026 (actual)
Oct 22, 2026
Primary completion
Jul 2027→Sep 23, 2027
Oct 22, 2026
Study completion
Jul 2027→Sep 23, 2027
Oct 22, 2026
Eligibility
1 inclusion criterion removed; 1 exclusion criterion added
What changed in the criteria
Inclusion criteria
  • RemovedSystolic blood pressure ≥ 100 mmHg.
Exclusion criteria
  • AddedPerson who objects to the processing of their data for quality control purposes
Oct 29, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedHandgrip stenght testTime frame: Day 1 and at the end of Week 3.
Oct 29, 2026
Contact
Study contact changed: g•••@chru-nancy.fr · •••7322→n•••@chru-nancy.fr · •••7496. See the current contact
Oct 29, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Centre Hospitalier Régional Universitaire de Nancy · Nancy, FranceContact g•••@chru-nancy.fr · •••7322→n•••@chru-nancy.fr · •••7496
Oct 29, 2026
Sponsor
BAUDRY Guillaume→Central Hospital, Nancy, France
Oct 22, 2026
Show all 2 updates
  1. Oct 29, 2026
    Eligibility 1 inclusion criterion removed; 1 exclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • RemovedSystolic blood pressure ≥ 100 mmHg.
    Exclusion criteria
    • AddedPerson who objects to the processing of their data for quality control purposes
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedHandgrip stenght testTime frame: Day 1 and at the end of Week 3.
    Contact Study contact changed: g•••@chru-nancy.fr · •••7322→n•••@chru-nancy.fr · •••7496. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Centre Hospitalier Régional Universitaire de Nancy · Nancy, FranceContact g•••@chru-nancy.fr · •••7322→n•••@chru-nancy.fr · •••7496
  2. Oct 22, 2026
    Not yet recruiting→Recruiting
    Centre Hospitalier Régional Universitaire de Nancy is now Recruiting
    Start date Apr 2026→Jun 23, 2026 (now actual)
    Primary completion Jul 2027→Sep 23, 2027
    Study completion Jul 2027→Sep 23, 2027
    Sponsor BAUDRY Guillaume→Central Hospital, Nancy, France
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07468344
Responsible party
BAUDRY Guillaume (Principal Investigator, Central Hospital, Nancy, France) — Principal investigator
First posted
Mar 12, 2026
Start date
Jun 23, 2026
Primary completion
Sep 23, 2027 (estimated)
Completion
Sep 23, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Nicolas Girerd
Contact
n.girerd@chru-nancy.fr
+33 03 83 15 74 96

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion